Heath Law Alliance is proud to announce a major legal victory on behalf of its pharmacy client in California: the full reversal of a Medi-Cal (California Medicaid) payment suspension imposed by the California Department of Health Care Services (DHCS).
Medi-Cal payment suspensions are serious administrative actions that can jeopardize a pharmacy’s business operations, reputation, and its ability to service its patients. These payment suspensions are often triggered by preliminary audit findings and/or other unverified suspicions of wrongdoing. In this case, DHCS initiated a payment suspension based on speculative allegations and incomplete evidence.
Heath Law Alliance intervened immediately. Our legal team crafted a number of strategic and persuasive appeals, demonstrating that the Department’s allegations failed to meet the legal standards required under both state and federal law. After a thorough review, the Office of Administrative Hearings and Appeals agreed with our position and issued a decision reversing the payment suspension in full.
This outcome underscores the importance of experienced legal counsel when dealing with Medicaid and/or any other insurance payors. It highlights our firm’s commitment to aggressive advocacy and unwavering defense of healthcare providers’ rights and business operations.
How Health Law Alliance Can Help
If your pharmacy is facing insurance payment suspensions, network terminations, investigations, and/or PBM audits, Heath Law Alliance stands ready to defend your practice and challenge unjust enforcement actions. With extensive experience in healthcare law, Medicaid and Medicare regulations, pharmacy provider defense, and litigation, our law firm is uniquely positioned to safeguard your interests and help secure the future of your pharmacy business.
Contact us today to schedule a free consultation.
MORE ARTICLES BY CATEGORY
Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing
Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.
Read More >>9th Circuit’s Landmark EKRA Ruling—What Providers Should Know
On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.
Read More >>Collateral Consequences Mount Quickly After Adverse DEA Inspection
Adverse findings during a DEA inspection can trigger a chain reaction of serious consequences for pharmacies, including increasing fines, suspension or revocation of DEA registrations and pharmacy licenses, costly False Claims Act (FCA) lawsuits, and potential criminal liability.
Read More >>Proposed HIPAA Security Rule Overhaul: What’s Changing - and Why Telehealth Providers Should Act Now
The proposed changes to the HIPAA Security Rule stand to have a significant impact on telehealth providers, as they aim to strengthen cybersecurity by making many previous guidelines mandatory and introducing new, more specific requirements. In this article, we outline seven key changes from the Proposed Rule and outline how providers can prepare their practices once the Rule is in effect.
Read More >>